As judged by the available literature, these agents have similar glucose-lowering effects, reducing HbA by around 0.5-1.5%.
However, the participants in these clinical trials had known diabetes of years’ duration, the effects of thiazolidinediones being more apparent when beta-cell function is less impaired.